In September 2018, FDA issued a new draft Guidance for Industry on Adaptive Designs for Clinical Trials of Drugs and Biologics. This guidance replaces the previously published 2010 draft guidance.
In this exclusive briefing note, Natasa Rajicic, Principal Strategic Consulting at Cytel summarizes the key similarities and differences between the two documents and highlights any significant new elements
introduced in the most recent material.
Complete the short form to download the briefing note.